ClinicalTrials.gg
RecruitingNCT05261139Updated Jul 17, 2025

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

A Phase 3 interventional study of nirmatrelvir and ritonavir in COVID-19, sponsored by Pfizer. Recruiting at 73 sites in 7 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing nirmatrelvir in COVID-19 — 3 open to participants now, 4 under way, 3 of them phase 3. nirmatrelvir · COVID-19.

Planned enrollment
8th of 22
160 · median 25
Started
2022
with 10 others
Phase 3
3 of 22
2 open now
Registered
13th of 22
by date
Lead sponsor
19 of 22
Pfizer

Among the 22 studies testing nirmatrelvir in COVID-19, this one is the 8th largest by planned enrollment, is one of 11 that started in 2022, is one of 3 in phase 3, and was the 13th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 22 studies testing nirmatrelvir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nirmatrelvir

nirmatrelvir: first FDA approval 2023 (PAXLOVID (COPACKAGED)), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing nirmatrelvir in COVID-19, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19).

The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)
  • Pediatrics
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female, age 0 to \< 18 years, able to swallow for some participants
  • Confirmed SARS-CoV-2 infection within 72 hours prior to enrollment
  • Initial onset of COVID-19 signs/symptoms within 5 days prior to the day of enrollment and at least 1 of the specified COVID-19 signs/symptoms present at enrollment
  • Has at least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19

Exclusion criteria

Exclusion Criteria:

  • History of or need for hospitalization for the medical treatment of COVID-19
  • Total >=2X (ULN) (except for Gilbert's syndrome)
  • Receiving dialysis or have known moderate to severe renal impairment
  • Suspected or confirmed concurrent active systemic infection other than COVID-19
  • History of or other to any of the components of the study intervention
  • Current or expected use of any medications or substances that are highly dependent on for clearance or strong inducers of cytochrome P450 (CYP)3A4
  • Has received or is expected to receive antibody treatment, antiviral treatment or convalescent COVID-19 plasma
  • Participating in another interventional clinical study with an compound or device, including those for COVID-19 through the study follow up
  • Females who are pregnant or breastfeeding
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Cohort 1 nirmatrelvir/ritonavir

    nirmatrelvir/ritonavir will be given by tablets or powder by mouth twice a day for 5 days (10 doses total). Weight ≥40 kg 1. ≥12 to \<18 years 2. ≥6 to \<12 years

    Drug: nirmatrelvir · Drug: ritonavir

  • Experimental
    Cohort 2 nirmatrelvir/ritonavir

    nirmatrelvir/ritonavir will be given as powder by mouth twice a day for 5 days (10 doses total) Weight ≥20 to \<40 kg, ≥6 to \<18 years

    Drug: nirmatrelvir · Drug: ritonavir

  • Experimental
    Cohort 3 nirmatrelvir/ritonavir

    nirmatrelvir/ritonavir ≥2 to \<6 years

    Drug: nirmatrelvir · Drug: ritonavir

  • Experimental
    Cohort 4 nirmatrelvir/ritonavir

    nirmatrelvir/ritonavir ≥1 month (≥28 days) to \<2 years

    Drug: nirmatrelvir · Drug: ritonavir

  • Experimental
    Cohort 5 nirmatrelvir/ritonavir

    nirmatrelvir/ritonavir \<1 month (\<28 days) old

    Drug: nirmatrelvir · Drug: ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir

    Time frame: Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose

  2. Cohort 1-2: Area Under the Curve to the End of the Dosing Period (AUC0-tau) of nirmatrelvir and ritonavir

    Time frame: Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose

  3. Incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuations.

    Time frame: From Baseline up through Day 34

  4. Incidence of Serious Adverse Events (SAEs) leading to discontinuations.

    Time frame: From Baseline up through Day 34

  5. Incidence of Adverse Events (AEs) leading to discontinuations.

    Time frame: From Baseline up through Day 34

  6. Number of participants with change from Baseline in Vital Signs

    Time frame: From Baseline up through Day 34

Secondary outcomes

  1. Viral load assessment titers measured via reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal or nasal swabs over time

    Time frame: Baseline, Day 5, 6, 10, 14 and 28

  2. Proportion of participants with COVID-19 related hospitalization or death from any cause

    Time frame: From Baseline through Day 28

  3. Patient assessment on acceptability and palatability of nirmatrelvir/ritonavir (film-coated tablets and oral powder)

    Frequency of responses to visual questionnaire on taste.

    Time frame: At baseline only for tablets and after each dose for powder formulation

07

Study locations

5 of 73 sites recruiting
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kaiser Permanente
    Los Angeles, California 90027, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UCLA David Geffen School of Medicine
    Los Angeles, California 90095, United States
    Not yet recruiting
  • UCLA
    Los Angeles, California 90095, United States
    Not yet recruiting
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Life Spring Research Foundation
    Miami, Florida 33130, United States
    Recruiting
  • Children's Healthcare of Atlanta - Arthur M. Blank Hospital
    Atlanta, Georgia 30329, United States
    Recruiting
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
  • Louisiana State University Health Sciences Shreveport
    Shreveport, Louisiana 71101, United States
    Recruiting
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Not yet recruiting
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Childrens Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
    Not yet recruiting
  • SKY Integrative Medical Center/SKYCRNG
    Ridgeland, Mississippi 39157, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St. Louis Children's Hospital
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Children's Hospital & Medical Center
    Omaha, Nebraska 68114, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of New Mexico Hospital, COVID-19 Research Clinic
    Albuquerque, New Mexico 87102, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of New Mexico Clinical and Translational Science Center
    Albuquerque, New Mexico 87106, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Suny University at Buffalo
    Buffalo, New York 14203, United States
    Not yet recruiting
  • Advanced Specialty Care
    Commack, New York 11725, United States
    Not yet recruiting
  • Stony Brook Medicine Clinical Research Center
    East Setauket, New York 11733, United States
    Not yet recruiting
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
    Not yet recruiting
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Not yet recruiting
  • Stony Brook University
    Stony Brook, New York 11794, United States
    Not yet recruiting
  • Upstate Health Care Center
    Syracuse, New York 13202, United States
    Not yet recruiting
  • Crouse Physicians Office Building
    Syracuse, New York 13210, United States
    Not yet recruiting
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
    Not yet recruiting
  • Upstate Golisano Children's Hospital
    Syracuse, New York 13210, United States
    Not yet recruiting
  • Clinical and Translational Research Center
    Chapel Hill, North Carolina 27514, United States
    Terminated

    Not enrolling at this site — choose another above.

  • investigational Drug Services Pharmacy, UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
    Terminated

    Not enrolling at this site — choose another above.

  • UNC Children's Hospital
    Chapel Hill, North Carolina 27514, United States
    Terminated

    Not enrolling at this site — choose another above.

  • UNC Global Clinical Research North
    Chapel Hill, North Carolina 27514, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27599, United States
    Terminated

    Not enrolling at this site — choose another above.

  • UNC Children's Raleigh
    Raleigh, North Carolina 27607, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UH Landerbrook Health Center
    Mayfield Heights, Ohio 44124, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UH Parma Medical Center
    Parma, Ohio 44129, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
    Not yet recruiting
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Miriam Hospital-Clinical Trials
    Providence, Rhode Island 02904, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Avera McKennan Hospital & University Health Center
    Sioux Falls, South Dakota 57105, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Avera Research Institute - Sioux Falls
    Sioux Falls, South Dakota 57108, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Texas Children's Hospital
    Houston, Texas 77030, United States
    Not yet recruiting
  • Biopharma Informatic, LLC
    McAllen, Texas 78503, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
    Recruiting
  • University of Utah
    Salt Lake City, Utah 84108, United States
    Not yet recruiting
  • МHAT "Sveti Ivan Rilski" Gorna Oryahovitsa
    Gorna Oryahovitsa, 5100, Bulgaria
    Not yet recruiting
  • "Specialized Hospital for Active Treatment of Pneumo-Physiatric Diseases Dr. Dimitar Gramatikov -
    Rousse, 7002, Bulgaria
    Not yet recruiting
  • Medical Center-1-Sevlievo EOOD
    Sevlievo, 5400, Bulgaria
    Not yet recruiting
  • DCC "Alexandrovska"
    Sofia, 1431, Bulgaria
    Terminated

    Not enrolling at this site — choose another above.

  • Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD
    Vratsa, 3000, Bulgaria
    Not yet recruiting
  • Tokyo Metropolitan Children's Medical Center
    Fuchū, Tokyo 183-8561, Japan
    Not yet recruiting
  • Osaka City General Hospital
    Osaka, 534-0021, Japan
    Not yet recruiting
  • Instituto Nacional de Pediatria
    Mexico City, Mexico City 04530, Mexico
    Not yet recruiting
  • Hospital Infantil de Mexico Federico Gomez
    Mexico City, Mexico City 06720, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • JM Research SC
    Cuernavaca, Morelos 62290, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fundación Santos y De la Garza Evia
    Monterrey, Nuevo León 64710, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Eukarya Pharmasite S.C.
    Monterrey, Nuevo León 64718, Mexico
    Terminated

    Not enrolling at this site — choose another above.

  • Unidad de Atención Médica e Investigación en Salud
    Mérida, Yucatán 97000, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kohler & Milstein Research S.A. De C.V.
    Mérida, Yucatán 97070, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatán S.
    Mérida, Yucatán 97130, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centenario Hospital Miguel Hidalgo
    Aguascalientes, 20259, Mexico
    Not yet recruiting
  • Arké SMO S.A de C.V
    Veracruz, 91900, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sociedad de Metabolismo y Corazon S.C.
    Veracruz, C.P. 91900, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • San Miguel Medical
    Trujillo Alto, 00976, Puerto Rico
    Not yet recruiting
  • Worthwhile Clinical Trials
    Benoni, Gauteng 1500, South Africa
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CRISMO Research Centre
    Germiston, Gauteng 1401, South Africa
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Botho Ke Bontle Health Services
    Pretoria, Gauteng 0184, South Africa
    Not yet recruiting
  • St. George's Hospital
    London, England SW17 0QT, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2026, 52 months after the start.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 52 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2022
First posted
Mar 2, 2022
StartActual
Mar 7, 2022
Primary completionEst.
Jul 30, 2026
CompletionEst.
Jul 30, 2026
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05261139
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Mar 7, 2022
Primary completion
Jul 30, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
Jul 17, 2025

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nirmatrelvir · Ritonavir

Start the discussion